Please Call Us for a Free Consultation (508)-720-9649

About Us

Advanced TMS associates brings together an experienced team of psychiatrists and certified neurotherapy technicians. Utilizing cutting-edge technology and advanced procedures, we have achieved significant results in treating patients suffering from depression and other neurological and psychiatric disorders. We work as a team in order to meet our goals of providing the highest quality services. We always strive to treat the patients under our care with the same degree of respect, compassion, and sensitivity which we would desire if we were receiving services in our clinic.

We provide TMS services to patients in Natick, Wellesley, Newton, Needham, Dedham, Framingham, Norwood, Westwood, Wayland, Sudbury, Dover, Hopkinton, Belmont and Brookline, MA as well as many other communities in the Metrowest and Greater Boston area.

Our Doctor

Gustavo Kinrys, M.D.
Dr. Kinrys is a graduate from the Mayo Clinic and the Massachusetts General Hospital. He is the Associate Medical Director of the MGH Clinical Trials Network and Institute (CTNI), and a member of the Bipolar Clinic and Research Program (BCRP), Massachusetts General Hospital. In addition, Dr. Kinrys has been a faculty at Harvard Medical School for over 15 years.

Currently, he is also an investigator in studies for the National Institutes of Mental Health and the Agency for Healthcare Research and Quality (AHRQ) involving the course and treatment of Bipolar disorder and Major depressive Disorder, including new magnetic-based technologies. Moreover, Dr. Kinrys is an investigator in numerous phase I, phase II, and phase III clinical trials sponsored by the pharmaceutical industry. Dr. Kinrys has published over 100 articles, reviews and posters, has been a recipient of numerous awards, and has delivered lectures in national and international forums. Dr. Kinrys has been the principal investigator in over 60 clinical trials. His areas of interest include treatment resistant depression, bipolar and anxiety disorders, development of novel pharmacologic agents and diagnostic tools for mood and anxiety disorders, cross-cultural and minority issues in clinical trials, and applications of natural remedies and new technologies alone and combined with conventional pharmacologic therapies for treatment-refractory patients.